Emcure Pharmaceuticals Limited has informed the Exchange regarding Re-appointment of Mr Mukund Gurjar as Executive Director of the company w.e.f. August 28, 2025.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals announced that its Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for a further period of one year starting August 28, 2025. Dr. Gurjar has been associated with Emcure since July 23, 2001, and currently serves as Executive Director and Chief Scientific Officer. He holds a PhD from Nagpur University and another from the University of London, and brings over 24 years of prior experience at the National Chemical Laboratory, Pune. The re-appointment is subject to approval from shareholders at the company's upcoming Annual General Meeting. He is not related to any other director on the Board.
This is a routine continuity announcement with no negative implications for shareholders. Retaining a long-serving scientific leader supports R&D stability, which is generally viewed as a neutral-to-slightly-positive signal for the company's long-term pipeline.